Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome
对于不适合接受强化化疗的急性髓系白血病 (AML) 和高危骨髓增生异常综合征 (MDS) 患者，无论 FLT3 突变状态如何，在 10 天地西他滨疗程中加入米哚妥林并不能改善预后。
期刊:Annals of Hematology
影响因子:2.4
doi:10.1007/s00277-024-06033-y
Huls, Gerwin; Chitu, Dana A; Tick, Lidwine; Boersma, Rinske; Breems, Dimitri; Herbers, Alexandra; Klein, Saskia K; de Jonge, Suzan; Westerweel, Peter E; Cruijsen, Marjan; Hoogendoorn, Mels; Cuijpers, Marlous; Deeren, Dries; Bailly, Benjamin; Visser, Otto; van Rhenen, Anna; Posthuma, Eduard F M; Valk, Peter J M; Cloos, Jacqueline; Ammatuna, Emanuele; Refos, Jeannine M; Fakkert, R; Löwenberg, Bob; Ossenkoppele, Gert J
